A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer.

Clinical trial NCT01602380 · COMPLETED

Trial details

NCT number: NCT01602380
Sponsor: AstraZeneca
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Hormone Receptor Positive Breast Cancer

Start date: 2012-10-17
Primary completion: 2016-04-11
Enrollment: 462

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.